meta_pixel
Tapesearch Logo
Log in
Planet Money

Two Indicators: The economics of innovation

Planet Money

NPR

Business, News

4.6 β€’ 29.8K Ratings

πŸ—“οΈ 14 June 2023

⏱️ 20 minutes

🧾️ Download transcript

Summary

Innovation is crucial for game-changing advancements in society, whether it's treatments for serious diseases, developments in AI technology, or rocket science.

Today on the show, we're airing two episodes from our daily economics show The Indicator. First, a new paper suggests that breakthrough innovations are more likely at smaller, younger companies. We talk to an inventor who left a big pharmaceutical company to start afresh, leading to some incredible treatments for serious diseases.

Then, it's off to Mars β€” or at least, on the way. Elon Musk's company SpaceX did a first test launch of a rocket meant to go all the way to the red planet. The rocket made it up off of the launch pad and lumbered briefly through the sky before self-destructing over the Gulf of Mexico. Suffice it to say, it's not quite ready. NPR science correspondent Geoff Brumfiel walks us through SpaceX's business plan as we try to figure out if this company has the funding and business acumen to reach its moonshot goal.

These two Indicator episodes were originally produced by Corey Bridges & Brittany Cronin, engineered by Katherine Silva & James Willets, and fact-checked by Dylan Sloan & Sierra Juarez. Kate Concannon edits the show.

The Planet Money version of this episode was produced by Willa Rubin, engineered by Robert Rodriguez, and edited by Keith Romer.


Help support Planet Money and get bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.

Transcript

Click on a timestamp to play from that location

0:00.0

This is Planet Money from NPR.

0:06.6

In the 1980s, Joshua Bojo was a chemist for the big pharmaceutical company Merck.

0:12.1

Joshua's job was to try to draw out new compounds and figure out if they could be used for new

0:18.0

medicines.

0:19.2

I was making 25 to 50 compounds a year.

0:23.7

By hand, one at a time, we were told that it would take about 50,000 compounds before

0:28.8

we should expect to get a drug.

0:30.8

So you do the math.

0:31.8

The average chemist would never make a drug in their entire career.

0:36.2

You can imagine him in a lab hoping to find a treatment one day for, say, HIV or hepatitis

0:42.8

C.

0:43.8

And he thought that a computer could help him with his quest.

0:47.4

So he got one.

0:49.2

Now picture this.

0:50.2

It's four decades ago.

0:51.3

The computer is like the size of a fridge.

0:53.6

He's ready to use it.

0:54.8

But there's a problem because he can't even plug it into the wall in a lab because he

0:59.6

needed a special electrical connection.

1:02.1

The people in charge said, we can't do that until we study the implications of this for

1:07.4

all of Merck's labs around the world.

1:10.1

And I just wanted a plug.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from NPR, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of NPR and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright Β© Tapesearch 2025.